Clinical trial
Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients
NCT00057447 · InterMune, Industry · Terminated
Key facts
| NCT number | NCT00057447 |
|---|---|
| Title | Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients |
| Official title | Phase I/II Study of the Safety of Subcutaneous Interferon Gamma-1b Combined With Rituximab in Patients With Low Grade/Follicular Non-Hodgkin's Lymphoma |
| Lead sponsor | InterMune, Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | Interferon Gamma-1b, Rituximab |
| Enrollment | 24 |
| Start date | Mar 1, 2003 |
| Completion | Jun 1, 2004 |
| First posted | Apr 3, 2003 |
| Last update posted | Nov 1, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: